Implementing an Individualized Pain Plan (IPP) for ED Treatment of VOE's in Sickle Cell Disease (ALIGN)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04584528 |
Recruitment Status :
Completed
First Posted : October 14, 2020
Last Update Posted : October 28, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Sickle Cell Disease Genetic Disease Hematologic Diseases Anemia, Sickle Cell | Other: Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP) | Not Applicable |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 279 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Intervention Model Description: | Multi-site pre-post study design, with a core set of mandatory patient and provider intervention strategies for each participating site, and optional strategies to allow for intervention adaptation to local needs and resources. |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Improving SCD Care Using Web-based Guidelines, Nurse Care Managers and Peer Mentors in Primary Care and Emergency Departments in Central North Carolina |
Actual Study Start Date : | October 27, 2020 |
Actual Primary Completion Date : | September 20, 2022 |
Actual Study Completion Date : | October 1, 2022 |

Arm | Intervention/treatment |
---|---|
EHR-embedded Individualized Pain Plan (IPP)
The EHR embedded IPP will be made accessible to patients and ED providers at each study site.
|
Other: Electronic Health Record (EHR) Embedded Individualized Pain Plan (IPP)
The IPPs will be developed by the Sickle Cell Disease providers at each study site based on patients' outpatient chronic opioid use and analgesic agent normally required for treatment of VOE in the ED. The Sickle Cell Disease provider will review the IPP with the patient, then upload the IPP to the patient's EHR in a location that will be accessible by the patient and ED provider. Each participating site will train patients and Emergency Department (ED) providers on how to access the IPP in the Electronic Health Record. The following required elements will be included in the EHR-embedded IPP:
If the enrolled patient has a VOE visit at a nonparticipating ED, the patient will be able to access their IPP via the web or the patient portal app through their EHR. However, data will not be collected from these visits. |
- Change in Patient-perceived quality of ED pain treatment. [ Time Frame: Baseline, 96 hours ]Three questions from the Adult Sickle Cell Quality of Life Measure (ASCQ-Me) and Quality of Care (QOC) measure will be used to measure the patient perceived quality of ED pain treatment
- ED revisit rate as measured by EHR retrieval [ Time Frame: Day 7 ]
- ED revisit rate as measured by EHR retrieval [ Time Frame: Day 30 ]
- Hospital readmission rate measured by EHR retrieval [ Time Frame: Day 7 ]
- Hospital readmission rate measured by EHR retrieval [ Time Frame: Day 30 ]
- Time to first dose of pain medication measured by EHR retrieval [ Time Frame: Baseline ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Patient Inclusion Criteria:
- Age 18 years up to and including 45 years
- English speaking
- Confirmed SCD diagnoses . Confirmed is defined as supported by documentation in the medical record of a positive test for one of the following : Hb SS, Hb SC, Hb S -thalassemia, Hb SO, Hb SD, Hb SG, Hb SE, or Hb SF.
- Access to a cellular/mobile smart phone with access to text messaging (either Android or iPhone acceptable) .
- At least one Vaso-Occlusive Episode (VOE) visit to participating site Emergency Department (ED) the past 90 days from enrollment
- At least one visit at the study site sickle cell disease clinic within the past 12 months
- Willing and cognitively able to give informed consent
Patient Exclusion criteria:
- Patient's sickle cell provider states patient should not have a protocol or should not be administered opioids
Provider Inclusion Criteria:
- Provides pain treatment in one of the participating study Emergency Departments for a patient participant with a qualified ED visit .

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04584528
United States, California | |
University of California San Francisco | |
Oakland, California, United States, 94609 | |
United States, Georgia | |
Georgia Regents University | |
Augusta, Georgia, United States, 30912 | |
United States, Illinois | |
University of Illinois | |
Chicago, Illinois, United States, 60612 | |
United States, Missouri | |
Washington University | |
Saint Louis, Missouri, United States, 63110 | |
United States, New York | |
Icahn School of Medicine at Mount Sinai | |
New York, New York, United States, 10029 | |
United States, North Carolina | |
Duke University | |
Durham, North Carolina, United States, 27710 | |
United States, South Carolina | |
Medical University of South Carolina | |
Charleston, South Carolina, United States, 29425 | |
United States, Tennessee | |
St. Jude's | |
Memphis, Tennessee, United States, 38105 |
Principal Investigator: | Paula Tanabe, PhD | Duke University School of Nursing |
Responsible Party: | Duke University |
ClinicalTrials.gov Identifier: | NCT04584528 |
Other Study ID Numbers: |
Pro00073506_1 5U01HL133964-05 ( U.S. NIH Grant/Contract ) |
First Posted: | October 14, 2020 Key Record Dates |
Last Update Posted: | October 28, 2022 |
Last Verified: | October 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | De-identified patient-level data will be available to researchers outside the SCDIC through an application and approval process as part of the SCDIC's Ancillary Studies Policy and Data Dissemination Plan. To protect the confidentiality and privacy of the participants, investigators granted access to the limited access data must adhere to strict requirements incorporated into a standard Data Use Agreement. In accordance with NHLBI policy, outside researchers will also be required to submit an approval tot RTI, the Data Coordinating Center, from their IRB. |
Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) Informed Consent Form (ICF) |
Time Frame: | Data will be made available by RTI, the data coordinating center for the study, upon request. |
Access Criteria: | Researches outside of the SCDIC must submit requests for de-identified study related data to RTI, the data coordinating center. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
sickle cell disease vaso occlusive-episodes Individualized Pain Plans implementation science |
Anemia, Sickle Cell Hematologic Diseases Genetic Diseases, Inborn Anemia, Hemolytic, Congenital |
Anemia, Hemolytic Anemia Hemoglobinopathies |